(Q49112239)
Statements
1 reference
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations. (English)
1 reference
Shun Matsuura
1 reference
Naoki Inui
1 reference
Yuichi Ozawa
1 reference
Yutaro Nakamura
1 reference
Mikio Toyoshima
1 reference
Kazumasa Yasuda
1 reference
Takashi Yamada
1 reference
Toshihiro Shirai
1 reference
Hideki Suganuma
1 reference
Koji Yokomura
1 reference
Takafumi Suda
1 reference
Kingo Chida
1 reference
28 June 2011
1 reference
41
1 reference
8
1 reference
959-963
1 reference
Identifiers
1 reference
1 reference